Fluorescein (Ophthalmic)

Fluorescein (Ophthalmic)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Fluorescein (Ophthalmic) is a contrast media that is FDA approved for the diagnosis of for testing tear film stability by determining the fluorescein break-up time (FBUT). Common adverse reactions include hypersensitivity.

• For testing tear film stability by determining the fluorescein break-up time (FBUT).

There is limited information regarding Off-Label Guideline-Supported Use of Fluorescein (Ophthalmic) in adult patients.

There is limited information regarding Off-Label Non–Guideline-Supported Use of Fluorescein (Ophthalmic) in adult patients.

There is limited information regarding FDA-Labeled Use of Fluorescein (Ophthalmic) in pediatric patients.

There is limited information regarding Off-Label Guideline-Supported Use of Fluorescein (Ophthalmic) in pediatric patients.

There is limited information regarding Off-Label Non–Guideline-Supported Use of Fluorescein (Ophthalmic) in pediatric patients.

• Hypersensitivity to components or mercury-containing compounds.

There is limited information regarding Fluorescein (Ophthalmic) Warnings' in the drug label.

There is limited information regarding Clinical Trial Experience of Fluorescein (Ophthalmic) in the drug label.

• Hypersensitivity

There is limited information regarding Fluorescein (Ophthalmic) Drug Interactions in the drug label.

Pregnancy Category (FDA): C

• Pregnancy Category

Pregnancy Category (AUS):

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Fluorescein (Ophthalmic) in women who are pregnant.

There is no FDA guidance on use of Fluorescein (Ophthalmic) during labor and delivery.

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to nursing mothers.

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to pediatric patients.

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to geriatric patients.

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to specific gender populations.

There is no FDA guidance on the use of Fluorescein (Ophthalmic) with respect to specific racial populations.

There is no FDA guidance on the use of Fluorescein (Ophthalmic) in patients with renal impairment.

There is no FDA guidance on the use of Fluorescein (Ophthalmic) in patients with hepatic impairment.

There is no FDA guidance on the use of Fluorescein (Ophthalmic) in women of reproductive potentials and males.

There is no FDA guidance one the use of Fluorescein (Ophthalmic) in patients who are immunocompromised.

• Ophthalmic

There is limited information regarding Monitoring of Fluorescein (Ophthalmic) in the drug label.

There is limited information regarding IV Compatibility of Fluorescein (Ophthalmic) in the drug label.

There is limited information regarding Fluorescein (Ophthalmic) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

• Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465-490 nm and fluoresces, i.e., emits light at wavelengths of 520-530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish-green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures.

There is limited information regarding Pharmacodynamics of Fluorescein (Ophthalmic) in the drug label.

There is limited information regarding Pharmacokinetics of Fluorescein (Ophthalmic) in the drug label.

There is limited information regarding Nonclinical Toxicology of Fluorescein (Ophthalmic) in the drug label.

There is limited information regarding Clinical Studies of Fluorescein (Ophthalmic) in the drug label.

• Carton of 50 pouches of two strips each.

There is limited information regarding Fluorescein (Ophthalmic) Storage in the drug label.

{{#ask: Page Name::Fluorescein (Ophthalmic) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

{{#ask: Label Page::Fluorescein (Ophthalmic) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

There is limited information regarding Patient Counseling Information of Fluorescein (Ophthalmic) in the drug label.

• Alcohol-Fluorescein (Ophthalmic) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

• DRY EYE TEST®^[1]

There is limited information regarding Fluorescein (Ophthalmic) Look-Alike Drug Names in the drug label.

The contents of this FDA label are provided by the National Library of Medicine.